Anebulo Pharmaceuticals (ANEB) 10-Q2024 Q1 Quarterly report

Filed: 14 Nov 23, 4:30pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Good

New words: activist, Addendum, adult, agitation, AI, allegedly, altogether, anniversary, annum, Anthony, Aron, Black, borrow, bound, Calloway, CCPA, COBRA, collateral, collateralized, Colorado, coma, comprise, conflict, covenant, CPRA, creditor, CTA, Cunningham, death, deceptive, deep, deficient, degradation, dispose, dollar, drawn, ED, EEA, English, equal, EU, Euro, external, fake, filer, fine, foreclosing, Framework, gather, GDPR, headcount, healthy, HITECH, honor, inconsistent, Irish, JFL, Kingdom, lawfully, leaked, Lender, levied, lien, Loan, loaned, LP, LSA, Maturity, media, member, misrepresentative, monumental, Nat, nearest, necessitate, notification, observational, pari, passed, pasu, path, pathway, pediatric, plasma, pro, quoted, randomized, rata, recovery, relocate, repeatedly, resigned, respiratory, revealed, Richard, Richie, rounded, social, statutory, store, tachycardia, temporary, threaten, UK, Undetected, Union, unused, vendor, Virginia, whichever, wiretapping

Removed: American, Certified, exercised, feet, Guide, illiquid, Institute, lease, Privately, square, valuation, vi, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ANEB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Anebulo Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, that to their knowledge:

(1) The Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2023

/s/ Richard Anthony Cunningham

Richard Anthony Cunningham

Chief Executive Officer

(Principal Executive Officer)

Date: November 14, 2023

/s/ Daniel George

Daniel George

Chief Financial Officer

(Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.